[ Back to EurekAlert! ] Public release date: 2-Jun-2010
[ | E-mail Share Share ]

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Columbia University Medical Center

NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting

NEW YORK (May 29, 2010) -- Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center will present their latest research findings at the American Urological Association's Annual Meeting in San Francisco, May 29 to June 3.

Dr. Steven Kaplan, a urologist and professor of urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr. Darracott Vaughan, senior author and professor emeritus of urology at Weill Cornell Medical College, have published data showing that 5-alpha reductase inhibitors (5-ARI), drugs used to control for benign prostatic hypertrophy (BPH), an enlarged prostate, may greatly improve the accuracy of traditional PSA tests for prostate cancer diagnosis.

"Taking 5-ARI drugs may eliminate the background noise associated with PSA testing -- canceling out a benign response and leaving only one signal for malignancy," explains Dr. Kaplan, lead author of the study. "Using PSA testing, we may now be able to distinguish prostate cancer from benign prostatic hyperplasia (BPH) disease."

Dr. Kaplan will present these potentially groundbreaking findings during a press briefing on June 1 at 1:00 p.m. PST and for meeting attendees on June 2 at 12:20 p.m. PST at Moscone North, 120 & 123.

Among the most significant presentations are the following.

###

NewYork-Presbyterian Hospital/Weill Cornell Medical Center

NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances -- including the development of the Pap test for cervical cancer; the synthesis of penicillin; the first successful embryo-biopsy pregnancy and birth in the U.S.; the first clinical trial for gene therapy for Parkinson's disease; the first indication of bone marrow's critical role in tumor growth; and, most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian/The Allen Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit www.nyp.org and www.med.cornell.edu.

Office of Public Affairs
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
525 East 68th Street, Box 144
New York, NY 10065

tel: 212.821.0560
fax: 212.821.0576
email: pr@nyp.org



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.